| ［1］ Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0［J］. J Am Acad Dermatol, 2012, 67(5): 1025-1039. DOI: 10.1016/j.jaad.2012.02.010.
［2］ Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors, and impact on overall survival［J］. Ann Oncol, 2003, 14(7): 1072-1077.
［3］ Lin NU, Carey LA, Liu MC, et al. Phase Ⅱ trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2positive breast cancer［J］. J Clin Oncol, 2008, 26(12): 1993-1999. DOI: 10.1200/JCO.2007.12.3588.
［4］ Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2positive advanced breast cancer［J］. N Engl J Med, 2006, 355(26): 2733-2743. DOI: 10.1056/NEJMoa064320.
［5］ Xu BH, Jiang ZF, Chua D, et al. Lapatinib plus capecitabine in treating HER2positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients［J］. Chin J Cancer, 2011, 30(5): 327-335.
［6］ Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER2［J］. Oncologist, 2008, 13(10): 1114-1119. DOI: 10.1634/theoncologist.2008-0816.
［7］ Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities［J］. Support Care Cancer, 2011, 19(8): 1079-1095. DOI: 10.1007/s00520-011-1197-6. |
